{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:42:03Z","timestamp":1787020923070,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["HRA-POR-2015-1099"],"award-info":[{"award-number":["HRA-POR-2015-1099"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["ILP-POR-2017-024"],"award-info":[{"award-number":["ILP-POR-2017-024"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["ERC-2007-StG 207777"],"award-info":[{"award-number":["ERC-2007-StG 207777"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","award":["16\/FRL\/3845"],"award-info":[{"award-number":["16\/FRL\/3845"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mesenchymal stromal cells (MSCs) demonstrate considerable promise for acute respiratory distress syndrome (ARDS) and sepsis. However, standard approaches to MSC isolation generate highly heterogeneous cell populations, while bone marrow (BM)\u00a0constitutes a limited and difficult to access MSC source. Furthermore, a range of cell manufacturing considerations and clinical setting practicalities remain to be explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Adult male rats were subject to\n                      <jats:italic>E. coli<\/jats:italic>\n                      -induced pneumonia and administered CD362\n                      <jats:sup>+<\/jats:sup>\n                      umbilical cord (UC)-hMSCs using a variety of cell production and clinical relevance considerations. In series 1, animals were instilled with\n                      <jats:italic>E<\/jats:italic>\n                      .\n                      <jats:italic>coli<\/jats:italic>\n                      and randomized to receive heterogeneous BM or UC-hMSCs or CD362\n                      <jats:sup>+<\/jats:sup>\n                      UC-hMSCs. Subsequent series examined the impact of concomitant antibiotic therapy, MSC therapeutic cryopreservation (cryopreserved vs fresh CD362\n                      <jats:sup>+<\/jats:sup>\n                      UC-hMSCs), impact of cell passage on efficacy (passages 3 vs 5 vs 7 vs 10), and delay of administration of cell therapy (0\u2009h vs 6\u2009h post-injury vs 6\u2009h\u2009+\u200912\u2009h) following\n                      <jats:italic>E<\/jats:italic>\n                      .\n                      <jats:italic>coli<\/jats:italic>\n                      installation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CD362\n                      <jats:sup>+<\/jats:sup>\n                      UC-hMSCs were as effective as heterogonous MSCs in reducing\n                      <jats:italic>E<\/jats:italic>\n                      .\n                      <jats:italic>coli<\/jats:italic>\n                      -induced acute lung injury, improving oxygenation, decreasing bacterial load, reducing histologic injury, and ameliorating inflammatory marker levels. Cryopreserved CD362\n                      <jats:sup>+<\/jats:sup>\n                      UC-hMSCs recapitulated this efficacy, attenuating\n                      <jats:italic>E<\/jats:italic>\n                      .\n                      <jats:italic>coli<\/jats:italic>\n                      -induced injury, but therapeutic relevance did not extend beyond passage 3 for all indices. CD362\n                      <jats:sup>+<\/jats:sup>\n                      UC-hMSCs maintained efficacy in the presence of antibiotic therapy and rescued the animal from\n                      <jats:italic>E<\/jats:italic>\n                      .\n                      <jats:italic>coli<\/jats:italic>\n                      injury when delivered at 6\u2009h\u2009+\u200912\u2009h, following\n                      <jats:italic>E<\/jats:italic>\n                      .\n                      <jats:italic>coli<\/jats:italic>\n                      instillation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      These translational studies demonstrated the efficacy of CD362\n                      <jats:sup>+<\/jats:sup>\n                      UC-hMSCs, where they decreased the severity of\n                      <jats:italic>E<\/jats:italic>\n                      .\n                      <jats:italic>coli<\/jats:italic>\n                      -induced pneumonia, maintained efficacy following cryopreservation, were more effective at early passage, were effective in the\u00a0presence of antibiotic therapy, and could continue to provide benefit at later time points following\n                      <jats:italic>E<\/jats:italic>\n                      .\n                      <jats:italic>coli<\/jats:italic>\n                      injury.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13287-020-01624-8","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T20:04:06Z","timestamp":1584129846000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Umbilical cord-derived CD362+ mesenchymal stromal cells for E. coli pneumonia: impact of dose regimen, passage, cryopreservation, and antibiotic therapy"],"prefix":"10.1186","volume":"11","author":[{"given":"Shahd","family":"Horie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Masterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Horan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"O\u2019Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Elliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Laffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"O\u2019Toole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,13]]},"reference":[{"issue":"3","key":"1624_CR1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccc.2011.04.004","volume":"27","author":"JE Gotts","year":"2011","unstructured":"Gotts JE, Matthay MA. Mesenchymal stem cells and acute lung injury. Crit Care Clin. 2011;27(3):719\u201333.","journal-title":"Crit Care Clin"},{"issue":"3","key":"1624_CR2","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.4049\/jimmunol.179.3.1855","volume":"179","author":"N Gupta","year":"2007","unstructured":"Gupta N, Su X, Popov B, Lee J, Serikov V, Matthay M. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol. 2007;179(3):1855\u201363.","journal-title":"J Immunol"},{"issue":"11","key":"1624_CR3","doi-asserted-by":"publisher","first-page":"L967","DOI":"10.1152\/ajplung.00144.2011","volume":"303","author":"L Ionescu","year":"2012","unstructured":"Ionescu L, Byrne R, van Haaften T, Vadivel A, Alphonse R, Rey-Parra G, et al. Stem cell conditioned medium improves acute lung injury in mice: in vivo evidence for stem cell paracrine action. Am J Physiol Lung Cell Mol Physiol. 2012;303(11):L967\u201377.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"2","key":"1624_CR4","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/SHK.0b013e3181d49457","volume":"34","author":"M Mao","year":"2010","unstructured":"Mao M, Wang S, Lv X, Wang Y, Xu J. Intravenous delivery of bone marrow-derived endothelial progenitor cells improves survival and attenuates lipopolysaccharide-induced lung injury in rats. Shock. 2010;34(2):196\u2013204.","journal-title":"Shock."},{"issue":"8","key":"1624_CR5","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1164\/rccm.201001-0010OC","volume":"182","author":"S Mei","year":"2010","unstructured":"Mei S, Haitsma J, Dos Santos C, Deng Y, Lai P, Slutsky A, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med. 2010;182(8):1047\u201357.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"1624_CR6","doi-asserted-by":"publisher","first-page":"L1003","DOI":"10.1152\/ajplung.00180.2011","volume":"302","author":"A Krasnodembskaya","year":"2012","unstructured":"Krasnodembskaya A, Samarani G, Song Y, Zhuo H, Su X, Lee J, et al. Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol. 2012;302(10):L1003\u201313.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"1","key":"1624_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00109-009-0523-7","volume":"88","author":"K Nemeth","year":"2010","unstructured":"Nemeth K, Mayer B, Mezey E. Modulation of bone marrow stromal cell functions in infectious diseases by toll-like receptor ligands. J Mole Med. 2010;88(1):5\u201310.","journal-title":"J Mole Med"},{"issue":"4","key":"1624_CR8","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1183\/09031936.00153211","volume":"40","author":"L Chimenti","year":"2012","unstructured":"Chimenti L, Luque T, Bonsignore MR, Ramirez J, Navajas D, Farre R. Pre-treatment with mesenchymal stem cells reduces ventilator-induced lung injury. Eur Respir J. 2012;40(4):939\u201348.","journal-title":"Eur Respir J"},{"issue":"11","key":"1624_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008013","volume":"4","author":"S Aguilar","year":"2009","unstructured":"Aguilar S, Scotton CJ, McNulty K, Nye E, Stamp G, Laurent G, et al. Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. PLoS One. 2009;4(11):e8013.","journal-title":"PLoS One"},{"issue":"14","key":"1624_CR10","doi-asserted-by":"publisher","first-page":"8407","DOI":"10.1073\/pnas.1432929100","volume":"100","author":"LA Ortiz","year":"2003","unstructured":"Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A. 2003;100(14):8407\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1624_CR11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/thoraxjnl-2011-201059","volume":"67","author":"GF Curley","year":"2012","unstructured":"Curley GF, Hayes M, Ansari B, Shaw G, Ryan A, Barry F, et al. Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat. Thorax. 2012;67(6):496\u2013501.","journal-title":"Thorax."},{"issue":"7","key":"1624_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/thoraxjnl-2015-206813","volume":"70","author":"J Devaney","year":"2015","unstructured":"Devaney J, Horie S, Masterson C, Elliman S, Barry F, O'Brien T, et al. Human mesenchymal stromal cells decrease the severity of acute lung injury induced by E. coli in the rat. Thorax. 2015;70(7):625\u201335.","journal-title":"Thorax."},{"issue":"1","key":"1624_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S2213-2600(14)70291-7","volume":"3","author":"JG Wilson","year":"2015","unstructured":"Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015;3(1):24\u201332.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"1624_CR14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S2213-2600(18)30418-1","volume":"7","author":"MA Matthay","year":"2019","unstructured":"Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019;7(2):154\u201362.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"1624_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315\u20137.","journal-title":"Cytotherapy."},{"issue":"3","key":"1624_CR16","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/ALN.0000000000002327","volume":"129","author":"C Masterson","year":"2018","unstructured":"Masterson C, Devaney J, Horie S, O'Flynn L, Deedigan L, Elliman S, et al. Syndecan-2-positive, bone marrow-derived human mesenchymal stromal cells attenuate bacterial-induced acute lung injury and enhance resolution of ventilator-induced lung injury in rats. Anesthesiology. 2018;129(3):502\u201316.","journal-title":"Anesthesiology."},{"issue":"2","key":"1624_CR17","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/cbin.10188","volume":"38","author":"Jie Hua","year":"2013","unstructured":"Hua J, Gong J, Meng H, Xu B, Yao L, Qian M, et al. Comparison of different methods for the isolation of mesenchymal stem cells from umbilical cord matrix: proliferation and multilineage differentiation as compared to mesenchymal stem cells from umbilical cord blood and bone marrow. Cell Biol Int. 2014;38(2):198\u2013210.","journal-title":"Cell Biology International"},{"issue":"2","key":"1624_CR18","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/jcb.23395","volume":"113","author":"C.Y. Fong","year":"2012","unstructured":"Fong CY, Gauthaman K, Cheyyatraivendran S, Lin HD, Biswas A, Bongso A. Human umbilical cord Wharton\u2019s jelly stem cells and its conditioned medium support hematopoietic stem cell expansion ex vivo. J Cell Biochem. 2012;113(2):658\u201368.","journal-title":"Journal of Cellular Biochemistry"},{"issue":"4","key":"1624_CR19","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/stem.2779","volume":"36","author":"SFH de Witte","year":"2018","unstructured":"de Witte SFH, Luk F, Sierra Parraga JM, Gargesha M, Merino A, Korevaar SS, et al. Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells. Stem Cells. 2018;36(4):602\u201315.","journal-title":"Stem Cells"},{"issue":"2","key":"1624_CR20","doi-asserted-by":"publisher","first-page":"R82","DOI":"10.1186\/cc12696","volume":"17","author":"J Devaney","year":"2013","unstructured":"Devaney J, Curley GF, Hayes M, Masterson C, Ansari B, O'Brien T, et al. Inhibition of pulmonary nuclear factor kappa-B decreases the severity of acute Escherichia coli pneumonia but worsens prolonged pneumonia. Crit Care. 2013;17(2):R82.","journal-title":"Crit Care"},{"issue":"7","key":"1624_CR21","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1097\/CCM.0b013e31817d1b59","volume":"36","author":"Donall F. O\u2019Croinin","year":"2008","unstructured":"O'Croinin DF, Nichol AD, Hopkins N, Boylan J, O'Brien S, O'Connor C, et al. Sustained hypercapnic acidosis during pulmonary infection increases bacterial load and worsens lung injury. Crit Care Med. 2008;36(7):2128\u201335.","journal-title":"Critical Care Medicine"},{"issue":"6","key":"1624_CR22","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1097\/ALN.0b013e3181ba3c11","volume":"111","author":"BD Higgins","year":"2009","unstructured":"Higgins BD, Costello J, Contreras M, Hassett P, O\u2019Toole D, Laffey JG. Differential effects of buffered hypercapnia versus hypercapnic acidosis on shock and lung injury induced by systemic sepsis. Anesthesiology. 2009;111(6):1317\u201326.","journal-title":"Anesthesiology."},{"issue":"8","key":"1624_CR23","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1097\/CCM.0b013e3181a385d3","volume":"37","author":"J Costello","year":"2009","unstructured":"Costello J, Higgins B, Contreras M, Chonghaile MN, Hassett P, O'Toole D, et al. Hypercapnic acidosis attenuates shock and lung injury in early and prolonged systemic sepsis. Crit Care Med. 2009;37(8):2412\u201320.","journal-title":"Crit Care Med"},{"issue":"5","key":"1624_CR24","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/jcb.22088","volume":"106","author":"Shobha Mareddy","year":"2009","unstructured":"Mareddy S, Broadbent J, Crawford R, Xiao Y. Proteomic profiling of distinct clonal populations of bone marrow mesenchymal stem cells. J Cell Biochem. 2009;106(5):776\u201386.","journal-title":"Journal of Cellular Biochemistry"},{"issue":"6","key":"1624_CR25","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/stem.1681","volume":"32","author":"Feng-Juan Lv","year":"2014","unstructured":"Lv FJ, Tuan RS, Cheung KM, Leung VY. Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells. 2014;32(6):1408\u201319.","journal-title":"STEM CELLS"},{"issue":"3","key":"1624_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/scrt68","volume":"2","author":"Svitlana Danchuk","year":"2011","unstructured":"Danchuk S, Ylostalo JH, Hossain F, Sorge R, Ramsey A, Bonvillain RW, et al. Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-alpha-induced protein 6. Stem Cell Res Ther. 2011;2(3):27.","journal-title":"Stem Cell Research & Therapy"},{"issue":"6","key":"1624_CR27","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/thoraxjnl-2011-201176","volume":"67","author":"Naveen Gupta","year":"2012","unstructured":"Gupta N, Krasnodembskaya A, Kapetanaki M, Mouded M, Tan X, Serikov V, et al. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax. 2012;67(6):533\u20139.","journal-title":"Thorax"},{"issue":"7","key":"1624_CR28","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1164\/rccm.201206-0990OC","volume":"187","author":"Jae W. Lee","year":"2013","unstructured":"Lee J, Krasnodembskaya A, McKenna D, Song Y, Abbott J, Matthay M. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med. 2013;187(7):751\u201360.","journal-title":"American Journal of Respiratory and Critical Care Medicine"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-020-01624-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13287-020-01624-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-020-01624-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T19:14:41Z","timestamp":1615576481000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-020-01624-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,13]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1624"],"URL":"https:\/\/doi.org\/10.1186\/s13287-020-01624-8","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,13]]},"assertion":[{"value":"15 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All work was approved by the Animal Care in Research Ethics Committee of the National University of Ireland, Galway, and licensed by the Health Products Regulatory Agency,","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Steve Elliman is the Chief Scientific Officer, Dr. Lisa O\u2019Flynn is the Head of Process Development, and Ms. Emma Horan is a Cell Manufacturing Technician at Orbsen Therapeutics Ltd., Galway, Ireland, a company which is developing the Syndecan-2 positive mesenchymal stromal cells for therapeutic purposes. Prof. Timothy O\u2019Brien and Prof. Frank Barry are directors of and equity holders in Orbsen Therapeutics. The other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}